Venetoclax/Venetoclax: Is it for chemotherapy or maintenance treatment?

Venetoclax/Venetoclax, this drug has attracted widespread attention in the pharmaceutical industry. So, is it a chemotherapy drug or a maintenance treatment drug? In fact, venetoclax is not a traditional chemotherapy drug, nor is it a pure maintenance treatment drug, but a type of targeted therapy.

Chemotherapy drugs usually work by killing fast-growing cells in the body, but this often inadvertently damages other normally fast-growing cells in the body, such as red blood cells and cells in hair, resulting in a series of side effects. The mechanism of action of venetoclax is completely different.

Veneclar works by binding to a specific protein calledBCL-2. This protein is overexpressed on cancer cells in patients with cancers such as acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). Venexaclat precisely kills cancer cells by inhibiting BCL-2, a group of proteins that regulate cell death by inhibiting or inducing apoptosis.

Compared with traditional chemotherapy drugs, due to its high degree of targeting, venetoclax causes significantly less damage to normal cells, so its side effects are relatively low. However, this does not mean that it does not have any side effects. During use, patients may experience adverse reactions such as bone marrow function suppression, such as reduction of white blood cells, neutrophils, and thrombocytopenia. In addition, symptoms such as anemia, pale complexion, and general weakness may also occur. In rare cases, allergic reactions such as skin itching and rash may occur.

In general, venetoclax/venetoclax, as a new type of targeted therapy, provides patients with new treatment options with its unique mechanism of action and low side effects.